Use: Labeled indications
- INDICATIONS AND USAGE ELIMITE ® (permethrin) 5% Cream is indicated for the treatment of infestation with Sarcoptes scabiei (scabies).
Full indications and usage US FDA label
INDICATIONS AND USAGE ELIMITE ® (permethrin) 5% Cream is indicated for the treatment of infestation with Sarcoptes scabiei (scabies).
Contraindications
CONTRAINDICATIONS ELIMITE ® (permethrin) 5% Cream is contraindicated in patients with known hypersensitivity to any of its components, to any synthetic pyrethroid or pyrethrin.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Adults and Children - Thoroughly massage ELIMITE ® (permethrin) 5% Cream into the skin from the head to the soles of the feet. Scabies rarely infests the scalp of adults, although the hairline, neck, temple, and forehead may be infested in infants and geriatric patients. Usually 30 grams is sufficient for an average adult.
The cream should be removed by washing (shower or bath) after 8 to 14 hours. Infants should be treated on the scalp, temple, and forehead. ONE APPLICATION IS GENERALLY CURATIVE. Patients may experience persistent pruritus after treatment. This is rarely a sign of treatment failure and is not an indication for retreatment. Demonstrable living mites after 14 days indicate that retreatment is necessary.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use - ELIMITE ® (permethrin) 5% Cream is safe and effective in pediatric patients two months of age and older. Safety and effectiveness in infants less than two months of age have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use - Clinical studies of ELIMITE ® (permethrin) 5% Cream did not identify sufficient numbers of subjects aged 65 and over to allow a definitive statement regarding whether elderly subjects respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
This drug is known to be substantially excreted by the kidney. However, since topical permethrin is metabolized in the liver and excreted in the urine as inactive metabolites, there does not appear to be an increased risk of toxic reactions in patients with impaired renal function when used as labeled.
Dosage forms
Philippines
- Lotion: 10 mg/mL, 50 mg/mL
- Cream: 50 mg/g
- Shampoo: 10 mg/mL
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Permethrin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
KwellPermethrin | 10 mg/mL ShampooPET/Aluminum/LLDPE - Sachet x 10 mL (Box of 24's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Aspen Philippines Inc. | DR-XY38145 | Jun 29, 2031 | |
LicegonePermethrin | 10 mg/mL LotionHDPE White Round Plastic Bottle with Cap x 50 mL (Box of 1's) | OTC | PT. Pharma Health CareMalaysia | Mursmedic Philippines Inc. | DR-XY49251 | Oct 10, 2029 | |
LindellPermethrin | 50 mg/mL (5%) LotionHDPE Bottle x 30 mL & 60 mL | OTC | Swiss Pharma Research Laboratories, Inc.Philippines | Britton Distributions, Inc.Trader: Neoderm, Inc. | DR-XY28601 | May 6, 2028 | |
PermetPermethrin | 50 mg/g (5%) CreamPolyethylene Tube x 5 g and 30 g | Rx | ZEE LABORATORIES LIMITEDIndia | EON PHARMATEK, INC | DR-XY42215 | Jul 18, 2028 | |
(no brand name)Permethrin | 50 mg/mL (5%) LotionWhite HDPE Bottle with White Screw Cap x 30 mL and 60 mL (Box of 1’s) | OTC | Lloyd Laboratories, Inc.Philippines | Brtitton Distributions, Inc.Trader: Neoderm, Incorporated | DR-XY480312 | May 20, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS If hypersensitivity to ELIMITE ® (permethrin) 5% Cream occurs, discontinue use.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS In clinical trials, generally mild and transient burning and stinging followed application with ELIMITE ® (permethrin) 5% Cream in 10% of patients and was associated with the severity of infestation. Pruritus was reported in 7% of patients at various times post-application. Erythema, numbness, tingling, and rash were reported in 1 to 2% or less of patients (see PRECAUTIONS: General).
Other adverse events reported since marketing ELIMITE ® (permethrin) 5% Cream include: headache, fever, dizziness, abdominal pain, diarrhea and nausea and/or vomiting. Although extremely uncommon and not expected when used as directed (see DOSAGE AND ADMINISTRATION), rare occurrences of seizure have been reported. None have been medically confirmed as associated with ELIMITE ® treatment.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy - Reproduction studies have been performed in mice, rats, and rabbits (200 to 400 mg/kg/day orally) and have revealed no evidence of impaired fertility or harm to the fetus due to permethrin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers - It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the evidence for tumorigenic potential of permethrin in animal studies, consideration should be given to discontinuing nursing temporarily or withholding the drug while the mother is nursing.
Pharmacokinetics
Permethrin is rapidly metabolized by ester hydrolysis to inactive metabolites which are excreted primarily in the urine.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods. It acts on the nerve cell membrane to disrupt the sodium channel current by which the polarization of the membrane is regulated. Delayed repolarization and paralysis of the pests are the consequences of this disturbance.
Permethrin is rapidly metabolized by ester hydrolysis to inactive metabolites which are excreted primarily in the urine. Although the amount of permethrin absorbed after a single application of the 5% cream has not been determined precisely, data from studies with 14 C-labeled permethrin and absorption studies of the cream applied to patients with moderate to severe scabies indicate it is 2% or less of the amount applied.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Permethrin Lotion 5%, 60 mL Bottle | ₱193.80–₱220.00Reference ₱205.80 | per bottle | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Permethrin |
| PNF listing | Lotion: 1%, 125 mL bottle |
| PNF listing | Lotion: 5%, 30 mL and 60 mL bottle Shampoo (Creme Rinse): |
| PNF listing | Lotion: 1%, 30 mL and 60 mL bottle |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ELIMITE · Aurobindo Pharma Limited [US FDA-approved label, version 1, January 24, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=443c0446-ccba-4f52-83ed-4c3163f35807
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .